Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.81 |
| ▸ | NPC1 | O15118 | 7/20 | 0.81 |
| ▸ | RAB9A | P51151 | 7/20 | 0.81 |
| ▸ | LMNA | P02545 | 5/20 | 0.81 |
| ▸ | RECQL | P46063 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.80 |
| ▸ | MEN1 | O00255 | 4/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.80 |
| ▸ | POLB | P06746 | 2/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.80 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.80 |
| ▸ | RELA | Q04206 | 1/20 | 0.80 |
| ▸ | XDH | P47989 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3134094 | 0.86 | MAPT (0.72) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL31084656 | 0.86 | MAPT (0.72) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL31084661 | 0.82 | RAB9A (0.56) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL25236610 | 0.82 | RAB9A (0.56) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL17412700 | 0.78 | RAB9A (0.54) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL17400475 | 0.77 | MPL (0.57) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL11874767 | 0.76 | ALDH1A1 (0.52) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL28822619 | 0.75 | MAPT (0.55) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL25279844 | 0.74 | RAB9A (0.59) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL8357836 | 0.74 | MAPT (0.59) | MAPTSMN1; SMN2NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353821-A1 | BENZENE SULFONAMIDE THIAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCERS | INST NAT SANTE RECH MED (FR) | 2025-11-20 | — | — | US | disclosed |
| EP-4452956-A1 | BENZENE SULFONAMIDE THIAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2024-10-30 | — | — | EP | disclosed |
| CN-118574812-A | Benzenesulfonamide thiazole compounds and their use for the treatment of cancer | 国家医疗保健研究所 | 2024-08-30 | — | — | CN | disclosed |
| WO-2023118373-A1 | BENZENE SULFONAMIDE THIAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-06-29 | — | — | WO | disclosed |
| EP-4201928-A1 | BENZENE SULFONAMIDE THIAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCERS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2023-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353821-A1 | BENZENE SULFONAMIDE THIAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCERS | HSPA5, HSP90B1, BAD | MAPT 2506/4885SMN1; SMN2 2588/4885NPC1 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.